1 / 20

MALIGNANT DISORDER OF THE UTERINE CORPUS

MALIGNANT DISORDER OF THE UTERINE CORPUS. Assoc. Prof. Gazi YILDIRIM, M.D. Yeditepe University, Medical Faculty Dept of Ob&Gyn. Objectives. To define Uterine cancer To learn Risk factors for endometrial cancer Prognostic factor for endometrial cancer Diagnosis of endometrial cancer

dabel
Download Presentation

MALIGNANT DISORDER OF THE UTERINE CORPUS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MALIGNANT DISORDER OF THE UTERINE CORPUS Assoc. Prof. Gazi YILDIRIM, M.D. Yeditepe University, Medical Faculty Dept of Ob&Gyn

  2. Objectives • To define • Uterinecancer • Tolearn • Risk factorsforendometrialcancer • Prognosticfactorforendometrialcancer • Diagnosisof endometrialcancer • Tomanage • A womanwithendometrial cancer

  3. Endometrial Carcinoma • The most common pelvic genital cancer in women. • White woman have 2.4% risk of endometrial carcinoma (Black woman 1.3%) • The peak incidence in the 7th decade • characterised by hyperplasia and anaplasia of the glanduler elements, with invasion of underlying stroma, myometrium and vascular spaces

  4. Risk Factors • Long term exposure to unopposed estrogens • polycystic ovarian syndrom • chronic anovulation • obesity • late menopause • exogenous estrogens) • Metabolic syndrome including diabetes, hypertension • Nulliparity • Increasing age • History of breast cancer • genetic predisposition • (hereditary nonpolyposis colon cancer syndrom) (HNPCC syndrom)  MSH2, MLH1, Ha-, K-, N-ras, c-myc, Her-2/neu, alterations in p53

  5. ETIOLOGY • Type I Endometrial carcinoma • Associated with either endogenous or exogenous unopposed estrogen exposure • low grade or well differentiated tumor with favourable prognosis. • Type II Endometrial carcinoma • Independent of estrogen • Associated with endometrial atrophy • High risk of relapse with poor prognosis.

  6. CLINICAL FINDINGS • Abnormal bleeding 80% of patients Most important and early symptom • Menorrhagia • Metrorrhagia • Postmenopausal bleeding • Lower abdominal cramps and pain 10% of patients It is secondary to uterine contractions caused by blood trapped behind a stenotic cervical os

  7. LABORATORY FINDINGS • Rutin laboratory are usually normal • Anemia may be present • Pap smear • CA 125

  8. SPECIAL EXAMINATIONS • main examination: endometrial sampling Fractional curretage Endometrial biopsy • Pipelle, novac curet, vabra aspirator • Pelvic ultrasonography • In postmenopausal woman endometrial thickness of more than 5 mm is considered to be suspicious for hyperplasia or malignancy • Estrogen and progesteron receptor assays • In general patiens with tumors positive for one or two receptors have longer survival than patients with receptor-negative tumors

  9. CLASSIFICATIONS-1 • Adenocarcinoma • The most common type (80%) • Adenocarcinoma with squamous differantitation • Serous carcinoma • identical to the serous carcinoma of ovary • 1-10% • Woman with serous carcinoma are more likely to be older and less likely to have hyperestrogenic states • spread early and involve peritoneal surfaces of the pelvis

  10. CLASSIFICATIONS-2 • Clear cell carcinoma • 1% of all endometrial carcinomas • Microscopic significance: clear cells or hobnail cells • Solid, papillary, tubular and cystic patterns • Commonly high grade and aggresive with deep invasion • older woman (average age: 67 years) • not associated with hyperestrogenic state.

  11. Route of Metastasis • Direct extension • Lymphatic metastasis • Peritoneal implants after transtubal spread • Hematogenous spread.

  12. Prognostic factors • Stage • Histologic grade • Cell type • Depth of myometrial invasion • Presence of lymphovascular space involvement • Lymph node status • Involvement of the lower uterine segment • Size of tumor • Tumor ploidy and the proportion of cells in S phase as determined by DNA flow cytometry

  13. Endometrium Kanseri Cerrahi Evrelemesi (FIGO2009) Evre1 : tm uterus korpusuna sınırlı G1 2 3 1a: myometrial invazyon yok veya <1/2’den az 1b: myometriumun =>1/2’si invaze Evre2: uterus korpusunu ve servikal stromayı tutar,uterusu aşmaz Evre3: pelvise rejyonel tm yayılımı 3a:seroza ve/veya adnekslere invazyon 3b: vajinal ve/veya parametrial metastaz 3c: pelvik ve/veya para-aortik lenf nodu metastazı 3c1: pelvik lenf nodu metastazı 3c2: para-aortik lenf nodu metastazı var, pelvik lenf nodu metastazı var veya yok Evre4: ilerlemiş pelvik hastalık veya uzak metastaz 4a:mesane ve/veya barsak mukozasında tümöral tutulum 4b: intraabdominal ve/veya inguinal lenf nodlarını içeren uzak metastazlar

  14. TREATMENT • Surgery • Radiation therapy • Hormone therapy • Chemotherapy

  15. SURGERY • The most important treatment modality total simple or radical hysterectomy, bilateral salpingooopherectomy staging, including pelvic and periaortic lymphadectomy

  16. Surgical Staging • who requires surgical staging? • Patients with stage I disease with grade 3 lesions • Tumor greater than 2 cm in maximum dimension • Tumors with greater than 50% myometrial invasion • Cervical extention • Evidence of extrauterine spread • Clear cell and papillary serous carcinomas because of high incidence of lymphatic spread

  17. RADIATION THERAPY • primary therapy in patients considered to be medically unstable for laparotomy • Adjuvant preoperative radiation is no longer used unless the patient presents with gross cervical involvement • Relative contraindications presense of pelvic mass, a pelvic kidney, pyometra, history of a pelvic abscess, prior pelvic radiation previous multiple laparotomies

  18. HORMONE THERAPY • Progesteron has shown some efficacy in the treatment of recurrent endometrial carcinoma not amenable to irradiation or surgery. • In patients with well differentiated estrogen receptor-positive tumors tamoxifen has been used either alone or in combination with progesterons.

  19. CHEMOTHERAPHY • Doxorubicin, cisplatin, taxol. • Doxorubicin  single agent response rate 38% • Doxorubicin + cysplatin  longer survival • Taxol + doxorubicin+ cisplatin  response rate 57%

  20. Uterine Sarcomas • Four categories; • leiomyosarcomas(LMSS) • endometrial stromal sarcomas (ESSS), • malignant mixed mesodermal tumors (MMMTS) • adenosarcoma

More Related